JP2020532532A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532532A5
JP2020532532A5 JP2020512430A JP2020512430A JP2020532532A5 JP 2020532532 A5 JP2020532532 A5 JP 2020532532A5 JP 2020512430 A JP2020512430 A JP 2020512430A JP 2020512430 A JP2020512430 A JP 2020512430A JP 2020532532 A5 JP2020532532 A5 JP 2020532532A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
aryl
independently
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512430A
Other languages
English (en)
Japanese (ja)
Other versions
JP7270608B2 (ja
JP2020532532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048705 external-priority patent/WO2019046511A1/en
Publication of JP2020532532A publication Critical patent/JP2020532532A/ja
Publication of JP2020532532A5 publication Critical patent/JP2020532532A5/ja
Priority to JP2023070638A priority Critical patent/JP7673118B2/ja
Application granted granted Critical
Publication of JP7270608B2 publication Critical patent/JP7270608B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512430A 2017-08-31 2018-08-30 化合物、組成物、及び疾患の治療方法 Active JP7270608B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023070638A JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762552473P 2017-08-31 2017-08-31
US62/552,473 2017-08-31
US201862664493P 2018-04-30 2018-04-30
US62/664,493 2018-04-30
PCT/US2018/048705 WO2019046511A1 (en) 2017-08-31 2018-08-30 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023070638A Division JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2020532532A JP2020532532A (ja) 2020-11-12
JP2020532532A5 true JP2020532532A5 (enExample) 2021-10-07
JP7270608B2 JP7270608B2 (ja) 2023-05-10

Family

ID=65526007

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512430A Active JP7270608B2 (ja) 2017-08-31 2018-08-30 化合物、組成物、及び疾患の治療方法
JP2023070638A Active JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023070638A Active JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Country Status (6)

Country Link
US (1) US11638716B2 (enExample)
EP (1) EP3675859A4 (enExample)
JP (2) JP7270608B2 (enExample)
CA (1) CA3074232A1 (enExample)
TW (1) TWI688390B (enExample)
WO (1) WO2019046511A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
EP3585379A4 (en) 2017-02-21 2020-12-02 Board of Regents, The University of Texas System CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
BR112020024605A2 (pt) 2018-06-01 2021-04-06 Eisai R&D Management Co., Ltd. Métodos para o tratamento de câncer de bexiga
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP7621974B2 (ja) * 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Stingモジュレータとしての修飾環状ジヌクレオシド化合物
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JPWO2021206158A1 (enExample) 2020-04-10 2021-10-14
CN115803032A (zh) 2020-05-15 2023-03-14 免疫传感器治疗股份有限公司 Sting激动剂与免疫检查点抑制剂的联合治疗
US20230256109A1 (en) 2020-08-07 2023-08-17 Tambo, Inc. Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy
US20230121320A1 (en) 2021-07-23 2023-04-20 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CA2899599A1 (en) 2013-02-18 2014-08-21 Spring Bank Pharmaceuticals, Inc. Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
CN105188373B (zh) 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
JP2016538344A (ja) * 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20170015353A (ko) 2014-06-04 2017-02-08 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Sting의 조절제로서 사이클릭 디­뉴클레오타이드
CH710524A2 (fr) 2014-12-18 2016-06-30 Swatch Group Res & Dev Ltd Résonateur d'horlogerie à lames croisées.
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック,インク. 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
BR112018002757A8 (pt) 2015-08-13 2023-04-11 Merck Sharp & Dohme Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
AU2016343993A1 (en) 2015-10-28 2018-05-10 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
JP6411676B2 (ja) * 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
CN106540260A (zh) 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白(sting)激动剂在抗阿尔兹海默症中的应用
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
KR20250049441A (ko) 2016-01-11 2025-04-11 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
KR20180114946A (ko) 2016-03-02 2018-10-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 sting 활성화 나노백신
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
EP3448393A1 (en) 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
EP3523287B1 (en) 2016-10-04 2021-09-01 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200113924A1 (en) 2016-12-20 2020-04-16 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
EP3585379A4 (en) 2017-02-21 2020-12-02 Board of Regents, The University of Texas System CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
KR20200028392A (ko) 2017-06-12 2020-03-16 유니버시티 오브 마이애미 질환의 치료를 위한 sting-의존성 활성화제
EP3642198B1 (en) 2017-06-22 2022-03-16 Curadev Pharma Limited Small molecule modulators of human sting
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの複素環式小分子調節因子
EP3642184A1 (en) 2017-06-22 2020-04-29 Curadev Pharma Limited Small molecule modulators of human sting
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
WO2019035901A1 (en) 2017-08-15 2019-02-21 University Of Miami COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
WO2019067468A1 (en) 2017-09-26 2019-04-04 La Jolla Institute For Allergy And Immunology MODULATION OF THE IMMUNE RESPONSE THROUGH THE STING PROTEIN
AU2018368789B2 (en) 2017-11-20 2022-06-02 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2019104353A1 (en) 2017-11-27 2019-05-31 Children's Medical Center Corporation Stimulator of interferon genes (sting) ligands and uses thereof
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
JP2021512144A (ja) 2018-01-26 2021-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California 環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
WO2019161171A1 (en) 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
AU2019225919B2 (en) 2018-02-21 2022-04-21 The Scripps Research Institute Agonists of stimulator of interferon genes sting
US20210017541A1 (en) 2018-03-26 2021-01-21 University Of Miami Recombinant viral vector and uses thereof
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
EP3774764A1 (en) 2018-04-03 2021-02-17 Merck Sharp&Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019234008A1 (en) 2018-06-04 2019-12-12 Aarhus Universitet Worm products and methods of use
EP3807264A1 (en) 2018-06-12 2021-04-21 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
CN108498529A (zh) 2018-06-20 2018-09-07 福建师范大学 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
JP7566731B2 (ja) 2018-07-03 2024-10-15 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
WO2020010451A1 (en) 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
CA3106731A1 (en) 2018-07-23 2020-01-30 Fosun Orinove Pharmatech, Inc. Ire1a inhibitor in combination with cancer therapeutic agent for cancer treatment

Similar Documents

Publication Publication Date Title
JP2020532532A5 (enExample)
JP2019532084A5 (enExample)
JP2017526677A5 (enExample)
JP2019511483A5 (enExample)
JP2019518766A5 (enExample)
JP2019527202A5 (enExample)
JP2020507589A5 (enExample)
JP2014521688A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2017531619A5 (enExample)
JP2005523922A5 (enExample)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2019526596A5 (enExample)
JP2013056886A5 (enExample)
JP2012519691A5 (enExample)
RU2012110007A (ru) Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor
JP2009513703A5 (enExample)
JP2014518882A5 (enExample)
JP2017515901A5 (enExample)
JP2012516900A5 (enExample)
JP2021502387A5 (enExample)
JP2016040288A5 (enExample)
JP2003530402A5 (enExample)
JP2013521291A5 (enExample)
JP2017517565A5 (enExample)